Flavio Salazar, Vice Rector at Universidad de Chile

Flavio Salazar, Vice Rector at Universidad de Chile

About

Dr. Flavio Salazar Onfray received his doctorate from the Karolinska Institute in Sweden in 1998. He returned to Chile in 1999 after obtaining a position in the Disciplinary Program of Immunology of the Institute of Biomedical Sciences, successfully establishing a productive multidisciplinary research group. His major interest has focused on several aspects of antitumor immunology, from basic research to clinical trials. Dr. Salazar described the effect of IL-10 cytokine on the inhibition of tumor-associated antigens and the evasion of tumors to the immune system (various articles in J. Exp. Med. 1994 and J. Immunol, 1997 -1998).

He also described the use of a peptide homologous to the functional domain of IL-10 demonstrating that it may affect the presentation of antigens in tumors and the maturation of dendritic cells (J. Immunol. (2004), Immunobiology (2011)). In addition to his group, he has identified and characterized a new melanoma antigen derived from the melanocortin 1 receptor (Brit J. cancer (2005), Immunobiology (2013)). Antibodies directed against this protein have been shown to be excellent for the diagnosis of ocular melanoma (IOVPS, 2007).

For the past ten years, Dr. Salazar has organized and led a multidisciplinary group of scientists including oncologists and immunologists, along with biologists and biochemists. Together they built the first GMP facilities for the manipulation of human cells and the first clinical trials were conducted in Chile Phase I and Phase I / II with dendritic cell-based immunotherapy for the treatment of melanoma and prostate cancer. The results of these studies have been published in high impact international journals, such as Clin. Exp. Immunol. (2005); J. Clin. Oncol. (2008); Clin. Cancer Res. (2011) and Cancer Immunol. Immunother. (2012, 2013) and Brit J Cancer (2013). He and his group patented an original method for producing dendritic cells ex vivo (PCT / EP2008 / 062909).

He also described the role of gap junctions in the interaction between human immune cells and tumors (J. Immunol 2007, J. Immunol. 2011, J. Immunol 2014). Dr. Salazar has been director of 10 doctoral theses, 5 of magister, more than 10 undergraduate and is highly committed to the training of young immunologists. Since 2005, Dr. Salazar (Deputy Director), together with Dr. Kalergis (Director) directs the Millennium Institute of Immunology and Immunotherapy.

He has been a referee of several international journals and also a member of the CONICYT study groups. He participates in several scientific societies and is a former president of the Chilean Society of Immunology and former President of the Latin American Association of Societies of Immunology (ALAI). He has directed research projects funded by national and international organizations (Cancerfonden Sweden, the University of Chile, FONDECYT Chile, Fondef Chile, CORFO and the Millennium). He has led several R & D projects, founding two spin off companies, Oncobiomed in 2002, dedicated to the transfer of technology and cellular immunotherapy and Bionex in 2007, dedicated to basic scientific advice for R & D projects. During the years 2007 And 2008,

In 2009 he was part of the delegation of the President of Chile during the State visit to India. He has published two books on cancer and is the author and co-author of over 40 scientific journals in international journals specializing in over 1600 citations.

Information

Industry experience

Education: PhD

Seniority: Board director, CEO, COO, CFO, President, Provost

Taxonomy